Y-Mabs Therapeutics (YMAB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating on the stock and has a $12.00 price target.
Robert Burns has given his Buy rating due to a combination of factors related to Y-Mabs Therapeutics’ promising pipeline and financial outlook. The company is expected to broaden its pipeline with upcoming catalysts, including a more mature data readout from the ongoing Phase 1/2 trial for the GD2-SADA program. This trial has shown promising pharmacokinetics and imaging data, indicating significant tumor uptake with minimal off-tumor localization. Additionally, Y-Mabs plans to disclose new potential high-value SADA PRIT targets and update its pipeline, with a steady submission of Investigational New Drug applications anticipated.
Financially, Y-Mabs reported a net loss in 4Q24 that was higher than forecasted, yet the sales of DANYELZA showed a substantial increase compared to the previous quarter. The company has also provided guidance for 2025, projecting significant revenue growth and manageable operating expenses. Despite adjustments in the valuation, including a delayed market entry for certain products and a reduced discount rate, Burns maintains a positive outlook on the stock, reiterating the Buy rating while adjusting the 12-month price target to $12.
In another report released on March 5, JonesTrading also reiterated a Buy rating on the stock with a $18.00 price target.
Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of YMAB in relation to earlier this year.